{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:09:46Z","timestamp":1790208586114,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K16602, 23K08382, 23K08332, 24K12068"],"award-info":[{"award-number":["22K16602, 23K08382, 23K08332, 24K12068"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Malignant hyperthermia (MH) is associated with mutations in the\n                      <jats:italic>RYR1<\/jats:italic>\n                      gene; however, the effect of volatile anesthetic concentrations on the clinical symptoms of patients with MH is unknown. We investigated the effects of high concentrations of volatile anesthetics on MH development and progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MH mouse models with R2509C mutation in\n                      <jats:italic>Ryr1<\/jats:italic>\n                      , all male, approximately 15\u00a0weeks old were administered 5%, 2.5% or 0.6% sevoflurane. The time at maximum temperature, maximum temperature, time at maximum heart rate, maximum heart rate, and time to asystole in the first experiment were measured. In the second experiment, blood samples were obtained from mice after the administration of 5% or 0.6% sevoflurane. In this experiment, the pH, base excess, and electrolyte and lactate levels were measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 16 mutant mice used, all showed elevation of heart rate and body temperature and went into asystole. The 0.6% group showed longer time at maximum temperature than the 5% group (68.0 [67.0, 72.0] min vs 43.5 [18.3, 47.8] min,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046); while, maximum temperature was higher in the 0.6% group than the other groups (40.2 [38.2, 40.8] \u00b0C in the 5% group, 42.4 [42.2, 42.6] \u00b0C in the 2.5% group, and 44.7 [43.6, 45.3] \u00b0C in the 0.6% group); maximum heart rate was lower in the 5% group (480 [465, 503] bpm in the 5% group, 630 [570, 630] bpm in the 2.5% group, and 630 [630, 660] bpm in the 0.6% group). In the second experiment, the 5% group showed lower base excess (-23.4 [-24.4, -22.3] mmol\/L vs -5.3 [-7.2, -4.3] mmol\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043) and higher lactate levels than the 0.6% group (20.00 [19.90, 20.00] mmol\/L vs 4.80 [4.35, 7.88] mmol\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022). Potassium was relatively higher in the 5% group than in the 0.6% group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When exposed to high concentrations of sevoflurane, MH developed and progressed rapidly; however, the maximum temperature was lower than that in cases of low-concentration exposure, likely due to the rapid progression of electrolyte abnormalities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-026-03779-y","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:24:18Z","timestamp":1774340658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of clinically relevant sevoflurane concentrations in the development of malignant hyperthermia in an Ryr1 mutant mouse model"],"prefix":"10.1186","volume":"26","author":[{"given":"Kenshiro","family":"Kido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Sumii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mukaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sotomaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo M.","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"3779_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1152\/physrev.00013.2002","volume":"82","author":"M Fill","year":"2002","unstructured":"Fill M, Copello JA. Ryanodine receptor calcium release channels. Physiol Rev. 2002;82:893\u2013922. https:\/\/doi.org\/10.1152\/physrev.00013.2002.","journal-title":"Physiol Rev"},{"key":"3779_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ceca.2004.08.001","volume":"37","author":"G Avila","year":"2005","unstructured":"Avila G. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved. Cell Calcium. 2005;37:121\u20137. https:\/\/doi.org\/10.1016\/j.ceca.2004.08.001.","journal-title":"Cell Calcium"},{"key":"3779_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-015-0310-1","volume":"10","author":"H Rosenberg","year":"2015","unstructured":"Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. https:\/\/doi.org\/10.1186\/s13023-015-0310-1.","journal-title":"Orphanet J Rare Dis"},{"key":"3779_CR4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S0140-6736(98)03078-5","volume":"352","author":"M Denborough","year":"1998","unstructured":"Denborough M. Malignant hyperthermia. Lancet. 1998;352:1131\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(98)03078-5.","journal-title":"Lancet"},{"key":"3779_CR5","doi-asserted-by":"publisher","first-page":"26965","DOI":"10.1074\/jbc.272.43.26965","volume":"272","author":"BR Fruen","year":"1997","unstructured":"Fruen BR, Mickelson JR, Louis CF. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem. 1997;272:26965\u201371. https:\/\/doi.org\/10.1074\/jbc.272.43.26965.","journal-title":"J Biol Chem"},{"key":"3779_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8340209","volume":"2023","author":"Y Toyota","year":"2023","unstructured":"Toyota Y, Kondo T, Shorin D, et al. Rapid dantrolene administration with body temperature monitoring is associated with decreased mortality in Japanese malignant hyperthermia events. BioMed Res Int. 2023;2023:8340209. https:\/\/doi.org\/10.1155\/2023\/8340209.","journal-title":"BioMed Res Int"},{"key":"3779_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/00000542-200503000-00007","volume":"102","author":"N Sambuughin","year":"2005","unstructured":"Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology. 2005;102:515\u201321. https:\/\/doi.org\/10.1097\/00000542-200503000-00007.","journal-title":"Anesthesiology"},{"key":"3779_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1213\/ANE.0000000000000886","volume":"121","author":"H Miyoshi","year":"2015","unstructured":"Miyoshi H, Yasuda T, Otsuki S, et al. Several ryanodine receptor type 1 gene mutations of p.Arg2508 are potential sources of malignant hyperthermia. Anesth Analg. 2015;121:994\u20131000. https:\/\/doi.org\/10.1213\/ANE.0000000000000886.","journal-title":"Anesth Analg"},{"key":"3779_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.nmd.2023.10.019","volume":"33","author":"Y Noda","year":"2023","unstructured":"Noda Y, Miyoshi H, Benucci S, et al. Functional characterization of RYR1 variants identified in malignant hyperthermia susceptible individuals. Neuromuscul Disord. 2023;33:951\u201363. https:\/\/doi.org\/10.1016\/j.nmd.2023.10.019.","journal-title":"Neuromuscul Disord"},{"key":"3779_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bja.2020.09.029","volume":"126","author":"H R\u00fcffert","year":"2021","unstructured":"R\u00fcffert H, Bastian B, Bendixen D, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126:120\u201330. https:\/\/doi.org\/10.1016\/j.bja.2020.09.029.","journal-title":"Br J Anaesth"},{"key":"3779_CR11","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202213136","volume":"154","author":"Y Tsuboi","year":"2022","unstructured":"Tsuboi Y, Oyama K, Kobirumaki-Shimozawa F, et al. Mice with R2509C-RYR1 mutation exhibit dysfunctional Ca2+ dynamics in primary skeletal myocytes. J Gen Physiol. 2022;154:e202213136. https:\/\/doi.org\/10.1085\/jgp.202213136.","journal-title":"J Gen Physiol"},{"key":"3779_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00540-009-0746-3","volume":"23","author":"T Migita","year":"2009","unstructured":"Migita T, Mukaida K, Hamada H, et al. Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon 47. J Anesth. 2009;23:341\u20136. https:\/\/doi.org\/10.1007\/s00540-009-0746-3.","journal-title":"J Anesth"},{"key":"3779_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24644-1","volume":"12","author":"T Yamazawa","year":"2021","unstructured":"Yamazawa T, Kobayashi T, Kurebayashi N, et al. A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke. Nat Commun. 2021;12:4293. https:\/\/doi.org\/10.1038\/s41467-021-24644-1.","journal-title":"Nat Commun"},{"key":"3779_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s1567-5769(01)00151-5","volume":"2","author":"NR Puig","year":"2002","unstructured":"Puig NR, Ferrero P, Bay ML, et al. Effects of sevoflurane general anesthesia: immunological studies in mice. Int Immunopharmacol. 2002;2:95\u2013104. https:\/\/doi.org\/10.1016\/s1567-5769(01)00151-5.","journal-title":"Int Immunopharmacol"},{"key":"3779_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00000542-199404000-00008","volume":"80","author":"MG Larach","year":"1994","unstructured":"Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771\u20139. https:\/\/doi.org\/10.1097\/00000542-199404000-00008.","journal-title":"Anesthesiology"},{"key":"3779_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3949\/ccjm.84a.17056","volume":"84","author":"BF Palmer","year":"2017","unstructured":"Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med. 2017;84:934\u201342. https:\/\/doi.org\/10.3949\/ccjm.84a.17056.","journal-title":"Cleve Clin J Med"},{"key":"3779_CR17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1213\/ANE.0000000000000421","volume":"119","author":"MG Larach","year":"2014","unstructured":"Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007\u20132012: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth Analg. 2014;119:1359\u201366. https:\/\/doi.org\/10.1213\/ANE.0000000000000421.","journal-title":"Anesth Analg"},{"key":"3779_CR18","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1097\/CCM.0000000000006401","volume":"52","author":"T Pinyavat","year":"2024","unstructured":"Pinyavat T, Riazi S, Deng J, et al. Malignant hyperthermia. Crit Care Med. 2024;52:1934\u201340. https:\/\/doi.org\/10.1097\/CCM.0000000000006401.","journal-title":"Crit Care Med"},{"key":"3779_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1213\/ANE.0000000000005837","volume":"135","author":"S Otsuki","year":"2022","unstructured":"Otsuki S, Miyoshi H, Mukaida K, Yasuda T, Nakamura R, Tsutsumi YM. Age-specific clinical features of pediatric malignant hyperthermia: a review of 187 cases over 60 years in Japan. Anesth Analg. 2022;135:128\u201335. https:\/\/doi.org\/10.1213\/ANE.0000000000005837.","journal-title":"Anesth Analg"},{"key":"3779_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.nmd.2022.06.003","volume":"32","author":"S Riazi","year":"2022","unstructured":"Riazi S, Bersselaar LRVD, Islander G, et al. Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH). Neuromuscul Disord. 2022;32:628\u201334. https:\/\/doi.org\/10.1016\/j.nmd.2022.06.003.","journal-title":"Neuromuscul Disord"},{"key":"3779_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3171\/jns.1988.68.2.0297","volume":"68","author":"T Feuerman","year":"1988","unstructured":"Feuerman T, Gade GF, Reynolds R. Stress-induced malignant hyperthermia in a head-injured patient. Case report. J Neurosurg. 1988;68:297\u20139. https:\/\/doi.org\/10.3171\/jns.1988.68.2.0297.","journal-title":"J Neurosurg"},{"key":"3779_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bjae.2023.11.001","volume":"23","author":"C Sellers","year":"2023","unstructured":"Sellers C, Woodman N. Inhalational induction in paediatric anaesthesia. BJA Educ. 2023;23:32\u20138. https:\/\/doi.org\/10.1016\/j.bjae.2023.11.001.","journal-title":"BJA Educ"},{"key":"3779_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/anae.15317","volume":"76","author":"PM Hopkins","year":"2021","unstructured":"Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: guideline from the Association of Anaesthetists. Anaesthesia. 2021;76:655\u201364. https:\/\/doi.org\/10.1111\/anae.15317.","journal-title":"Anaesthesia"},{"key":"3779_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/genes14112009","volume":"14","author":"H Miyoshi","year":"2023","unstructured":"Miyoshi H, Otsuki S, Mukaida K, et al. Effects of remimazolam on intracellular calcium dynamics in myotubes derived from patients with malignant hyperthermia and functional analysis of type 1 ryanodine receptor gene variants. Genes. 2023;14:2009. https:\/\/doi.org\/10.3390\/genes14112009.","journal-title":"Genes"},{"key":"3779_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8845129","volume":"2021","author":"T Watanabe","year":"2021","unstructured":"Watanabe T, Miyoshi H, Noda Y, et al. Effects of remimazolam and propofol on Ca2+ regulation by ryanodine receptor 1 with malignant hyperthermia mutation. Biomed Res Int. 2021;2021:8845129. https:\/\/doi.org\/10.1155\/2021\/8845129.","journal-title":"Biomed Res Int"},{"key":"3779_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/bja\/aer132","volume":"107","author":"PM Hopkins","year":"2011","unstructured":"Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth. 2011;107:48\u201356. https:\/\/doi.org\/10.1093\/bja\/aer132.","journal-title":"Br J Anaesth"},{"key":"3779_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211044201","volume":"49","author":"JY Min","year":"2021","unstructured":"Min JY, Hong SH, Kim SJ, Chung MY. Delayed-onset malignant hyperthermia in the postanesthetic care unit: a case report. J Int Med Res. 2021;49:3000605211044201. https:\/\/doi.org\/10.1177\/03000605211044201.","journal-title":"J Int Med Res"},{"key":"3779_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1213\/ANE.0000000000000062","volume":"118","author":"M Visoiu","year":"2014","unstructured":"Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014;118:388\u201396. https:\/\/doi.org\/10.1213\/ANE.0000000000000062.","journal-title":"Anesth Analg"},{"key":"3779_CR29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1177\/0310057X1504300415","volume":"43","author":"L Heytens","year":"2015","unstructured":"Heytens L, Forget P, Scholt\u00e8s JL, Veyckemans F. The changing face of malignant hyperthermia: less fulminant, more insidious. Anaesth Intensive Care. 2015;43:506\u201311. https:\/\/doi.org\/10.1177\/0310057X1504300415.","journal-title":"Anaesth Intensive Care"},{"key":"3779_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00000542-200608000-00009","volume":"105","author":"SC Manyam","year":"2006","unstructured":"Manyam SC, Gupta DK, Johnson KB, et al. Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. Anesthesiology. 2006;105:267\u201378. https:\/\/doi.org\/10.1097\/00000542-200608000-00009.","journal-title":"Anesthesiology"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-026-03779-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-03779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-03779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:45:21Z","timestamp":1781642721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12871-026-03779-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3779"],"URL":"https:\/\/doi.org\/10.1186\/s12871-026-03779-y","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with the ethical guidelines for animal research and approved by the Hiroshima University Animal Research Committee (Approval No. A23-60\u20132). Recombinant DNA experiments were approved by the Hiroshima University Safety Committee for Living Modified Organisms (Approval No. 2023\u2013107-2). The mutant mice were originally owned by Department of Neuromuscular Research, National Center of Neurology and Psychiatry (NCNP), National Institute of Neuroscience (Tokyo, Japan), and we obtained informed consent to use the mice in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}